Abstract:

Objective　To investigate the clinical effect of ozagrel trometamol and clopidogrel bisulfate dual antiplatelet therapy combined with traditional Chinese medicine in the treatment of progressive ischemic stroke. Methods　A total of 100 patients with progressive ischemic stroke without intravenous thrombolysis or intravascular thrombolysis were selected from Guangdong Sanjiu Brain Hospital from January 2022 to January 2023. The patients were divided into a control group (50 cases) and an experimental group (50 cases) by the random number table method. There were 23 males and 27 females in the experimental group, aged (62.21±10.77) years. There were 26 males and 24 females in the control group, aged (60.52±11.27) years. The control group was treated with clopidogrel bisulfate + ginkgo diterpene lactone meglumine, and the experimental group was treated with ozagrel trometamol on the basis of the control group. Both groups were treated for 14 days. The scores of National Institutes of Health Stroke Scale (NIHSS) and Barthel index (BI) of daily living ability before and after treatment, treatment effect, and occurrence of adverse drug reactions during treatment were compared between the two groups. Independent sample t test, paired t test, and χ² test were used for statistical analysis. Results　After treatment, the NIHSS score of the experimental group was lower than that of the control group [(16.62±3.07) points vs. (21.13±3.27) points], and the BI score of the experimental group was higher than that of the control group [(90.17±7.25) points vs. (84.41±7.05) points] (both P<0.05). The total effective rate of the experimental group was higher than that of the control group [90.00% (45/50) vs. 50.00% (25/50)] (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups [4.00% (2/50) vs. 0] (P>0.05). Conclusion　Ozagrel trometamol and clopidogrel bisulfate dual antiplatelet therapy combined with traditional Chinese medicine has a good effect on the treatment of progressive ischemic stroke, which has reference significance for the clinical treatment of progressive ischemic stroke.

Key words:

Progressive ischemic stroke, Ozagrel trometamol, Clopidogrel bisulfate, Dual antiplatelet therapy

摘要：

目的　探讨奥扎格雷氨丁三醇、硫酸氢氯吡格雷双重抗血小板联合中药治疗进展性缺血性脑卒中的临床效果。方法　选取2022年1月至2023年1月广东三九脑科医院收治的100例未经静脉溶栓及血管内取栓的进展性缺血性脑卒中患者。采用随机数字表法，将患者分为对照组（50例）和试验组（50例）。试验组男23例，女27例；年龄（62.21±10.77）岁。对照组男26例，女24例；年龄（60.52±11.27）岁。对照组采用硫酸氢氯吡格雷+银杏二萜内酯葡胺治疗，试验组在对照组基础上采用奥扎格雷氨丁三醇治疗。两组均连续治疗14 d。比较两组治疗前后美国国立卫生研究院卒中量表（NIHSS）、日常生活能力Barthel指数（BI）评分，治疗效果，治疗期间药物不良反应发生情况。采用独立样本t检验、配对t检验和χ²检验进行统计学分析。结果　治疗后，试验组NIHSS评分低于对照组［（16.62±3.07）分比（21.13±3.27）分］，BI评分高于对照组［（90.17±7.25）分比（84.41±7.05）分］（均P<0.05）。试验组治疗总有效率高于对照组［90.00%（45/50）比50.00%（25/50）］（P<0.05）。两组不良反应总发生率比较，差异无统计学意义［4.00%（2/50）比0］（P>0.05）。结论　奥扎格雷氨丁三醇、硫酸氢氯吡格雷双重抗血小板联合中药治疗进展性缺血性脑卒中效果较好，对临床治疗进展性缺血性脑卒中具有借鉴意义。

关键词:

进展性缺血性脑卒中, 奥扎格雷氨丁三醇, 硫酸氢氯吡格雷, 抗血小板聚集